Abstract: The present disclosure relates to an image processing method. The method may include: obtaining image data; reconstructing an image based on the image data, the image including one or more first edges; obtaining a model, the model including one or more second edges corresponding to the one or more first edges; matching the model and the image; and adjusting the one or more second edges of the model based on the one or more first edges.

Abstract: The present disclosure relates to an image processing method. The method may include: obtaining image data; reconstructing an image based on the image data, the image including one or more first edges; obtaining a model, the model including one or more second edges corresponding to the one or more first edges; matching the model and the image; and adjusting the one or more second edges of the model based on the one or more first edges.

Abstract: The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, R3, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLA2 inhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLA2 enzyme.

Abstract: The present disclosure discloses a method for generating color medical image. The method for generating color medical image comprising: acquiring medical image data, segmenting at least one tissue in the medical image data, determining a combined color table from a combined color table database based on the at least one tissue; and generating a color medical image based on the combined color table. In some embodiments, the combined color table comprises data of color schemes for the segmented tissues.

Abstract: The present disclosure relates to an image processing method. The method may include: obtaining image data; reconstructing an image based on the image data, the image including one or more first edges; obtaining a model, the model including one or more second edges corresponding to the one or more first edges; matching the model and the image; and adjusting the one or more second edges of the model based on the one or more first edges.

Abstract: A method for image segmentation may include acquiring an image including a region of interest (ROI). The ROI has a first margin, the ROI includes a subregion, and the subregion has a second margin. The method may further include acquiring a first model according to the ROI, wherein the first model has a third margin. The method may further determine, based on the first margin and the third margin, a second model by matching the first model with the image, wherein the second model includes a sub-model, and the sub-model has a fourth margin. The method may further include determining, based on the second margin, a third model by adjusting the fourth margin of the sub-model in the second model. The method may further include segmenting the ROI according to the third model and generating a segmented ROI based on a result of the segmentation.

Abstract: The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, R3, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLA2 inhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLA2 enzyme.

Abstract: The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, R3, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLA2 inhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLA2 enzyme.

Abstract: A method for image segmentation may include acquiring an image including a region of interest (ROI). The ROI has a first margin, the ROI includes a subregion, and the subregion has a second margin. The method may further include acquiring a first model according to the ROI, wherein the first model has a third margin. The method may further determine, based on the first margin and the third margin, a second model by matching the first model with the image, wherein the second model includes a sub-model, and the sub-model has a fourth margin. The method may further include determining, based on the second margin, a third model by adjusting the fourth margin of the sub-model in the second model. The method may further include segmenting the ROI according to the third model and generating a segmented ROI based on a result of the segmentation.

Abstract: The present disclosure discloses a method for generating color medical image. The method for generating color medical image comprising: acquiring medical image data, segmenting at least one tissue in the medical image data, determining a combined color table from a combined color table database based on the at least one tissue; and generating a color medical image based on the combined color table. In some embodiments, the combined color table comprises data of color schemes for the segmented tissues.

Abstract: The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, R3, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLA2 inhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLA2 enzyme.

Abstract: The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I), or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. In one embodiment, the compound is represented by Structural Formula (II), or a prodrug, isomer, ester, salt, hydrate, solvate or polymorph thereof. The present invention also provides a pharmaceutical composition comprising the compound of the invention and method of use thereof.

Abstract: A method and system for extracting coronary artery centerlines from 3D medical image volumes is disclosed. Heart chambers are segmented in a 3D volume. Coronary artery centerlines are initialized in the 3D volume coronary artery based on the segmented heart chambers. The coronary artery centerlines are locally refined based on a vesselness measure. A length of each coronary artery centerline is shrunk to verify that the coronary artery centerline is within a coronary artery. The coronary artery centerline is the extended using data-driven vessel tracing.

Abstract: The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof.

Abstract: Certain bis[thio-hydrazide amide]-related compounds are found to be surprisingly effective at treating with leukemia, e.g., acute myeloid leukemia (AML). Methods of treating a subject with AML including administering bis[thio-hydrazide amide]-related compounds described herein, are disclosed.

Abstract: The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof.

Abstract: The present invention relates to the field of pharmaceutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) and a preparation method thereof, a pharmaceutical composition with the compounds as active components, and a use of the azole compounds and the pharmaceutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as defined in the specification.

Abstract: The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof.

Abstract: The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compounds. The compounds are useful as PPAR? agonist, through activating PPAR-RXR heterodimers that interacts with specific DNA response elements within promoter regions of target gene, particularly in the treatment and prevention of polycystic kidney and cancer.

Abstract: The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof.